DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis

Clinical and Experimental Immunology

Volumn 163, Issue 1, 2011, Pages 113-122

  Ohkawara, T ^a,b   Koyama, Y ^a   Onodera, S ^b   Takeda, H ^c   Kato, M ^d   Asaka, M ^b   Nishihira, J ^a  

^a HOKKAIDO INFORMATION UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colitis; Inflammatory bowel disease; Macrophage migration inhibitory factor; Th epitope; Vaccine

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; DEXTRAN SULFATE; DNA VACCINE; EPITOPE; MACROPHAGE MIGRATION INHIBITION FACTOR; MYELOPEROXIDASE; OLIGONUCLEOTIDE; PLASMID DNA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; COLITIS; COLON; CONTROLLED STUDY; DNA IMMUNIZATION; ELECTROPORATION; ENZYME ACTIVITY; HELPER CELL; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; COLITIS; CYTOKINES; DEXTRAN SULFATE; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED BALB C; PEROXIDASE; VACCINES, DNA;

EID: 78649743117     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04277.x     Document Type: Article

References (37)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
2. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92 (Suppl 12):S5-11.
3. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51:289-98.
4. Targan SR, Hanauer SB, Van Deventer SJ et al. A short- term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
5. Van Dullemen HM, Van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-35.
6. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 2000; 21:397-402.
7. Bucala R. MIF rediscovered: pituitary hormone and glucocorticoid- induced regulator of cytokine production. FASEB J 1996; 7:19-24.
8. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000; 20:751-62.
9. Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. Drug News Perspect 2005; 18:417-26.
10. Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 2001; 31:337-43.
11. De Jong YP, Abadia- Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001; 2:1061-6.
12. Ohkawara T, Nishihira J, Takeda H et al. Amelioration of dextran sulfate sodium- induced colitis by anti- macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002; 123:256-70.
13. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Macrophage migration inhibitory factor activates antigen- presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 2002; 128:504-10.
14. Nohara H, Okayama N, Inoue N et al. Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004; 39:242-6.
15. Dambacher J, Staudinger T, Seiderer J et al. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13:71-82.
16. Ohkawara T, Nishihira J, Ishiguro Y et al. Resistance to experimental colitis depends on cytoprotective heat shock proteins in macrophage migration inhibitory factor null mice. Immunol Lett 2006; 107:148-54.
17. Onodera S, Ohshima S, Toyama H et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 2007; 56:521-30.
18. Hamasaka A, Abe R, Koyama Y et al. DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models. J Allergy Clin Immunol 2009; 124:90-9.
19. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
20. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-50.
21. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867-70.
22. Ohkawara T, Miyashita K, Nishihira J et al. Transgenic over- expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol 2005; 140:241-8.
23. Makita H, Nishimura M, Miyamoto K et al. Effect of anti- macrophage migration inhibitory factor antibody on lipopolysaccharade- induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158:573-9.
24. Calandra T, Echtenacher B, Roy DL et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-70.
25. Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999; 29:1752-9.
26. Ohkawara T, Mitsuyama K, Takeda H, Asaka M, Fujiyama Y, Nishihira J. Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium- induced colitis. Scand J Gastroenterol 2008; 43:1497-504.
27. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87:1344-50.
28. Dalum I, Jensen MR, Hindersson P, Elsner HI, Mouritsen S. Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 1996; 157:4796-804.
29. Dalum I, Jensen MR, Gregorius K, Thomasen CM, Elsner HI, Mouritsen S. Induction of cross- reactive antibodies against a self protein containing a foreign T helper epitope. Mol Immunol 1997; 34:1113-20.
30. Dalum I, Butler DM, Jensen MR et al. Therapeutic antibodies elicited by immunization against TNF- α. Nat Biotechnol 1999; 17:666-9.
31. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997; 60:163-72.
32. Youssef S, Wildbaum G, Maor G et al. Long- lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C- C chemokines. J Immunol 1998; 161:3870-9.
33. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004; 99:201-16.
34. Hertz M, Mahalingam S, Dalum I et al. Active vaccination against IL- 5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001; 167:3792-9.
35. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83:147-52.
36. Girard M, Yue L, Barré- Sinoussi F et al. Failure of a human immunodeficiency virus type 1 (HIV- 1) subtype B- derived vaccine to prevent infection of chimpanzees by an HIV- 1 subtype E strain. J Virol 1996; 70:8229-33.
37. Vandepapeliere P, Barrasso R, Meijer CJ et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005; 192:2099-107.